NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 70 resultados LastUpdate Última actualización 21/09/2018 [14:07:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


PROCESSES FOR THE DIAGNOSIS, PROGNOSIS AND MONITORING OF THE PROGRESSION OF CHRONIC LYMPHOID LEUKAEMIA (CLL) AND/OR OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) USING MEMBRANE STIM 1

NºPublicación: US2018267035A1 20/09/2018

Solicitante:
UNIV DE BRETAGNE OCCIDENTALE UBO [FR]
INST NAT SANTE RECH MED [FR]
CENTRE HOSPITALIER REGIONAL ET UNIV DE BREST [FR]

Resumen de: US2018267035A1

Some embodiments are directed to a process for the diagnosis of systemic lupus erythematosus (SLE) and/or of chronic lymphoid leukaemia (CLL) of a subject who may be suffering therefrom, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane in a biological sample from human and mice. Some other embodiments are directed to a process for predicting the progression and/or monitoring the progression of CLL and/or of SLE, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane.



traducir


 

COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS

NºPublicación: US2018263970A1 20/09/2018

Solicitante:
BROAD INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]
HARVARD COLLEGE [US]
BAYER PHARMA AG [DE]

Resumen de: US2018263970A1

The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).



traducir


 

KIR3DL1/HLA-B SUBTYPESFOR HEMATOPOIETIC CELL TRANSPLANTATION DONOR SELECTION

NºPublicación: WO2018169793A1 20/09/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: WO2018169793A1

The present disclosure relates generally to methods for treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of hematopoietic cells obtained from a candidate donor having a specific combination of KIR3DL1 and HLA-B alleles. Also disclosed herein are methods for protecting a leukemia patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT).



traducir


 

METHODS FOR THE DIAGNOSIS AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA ASSOCIATED NEURAL REMODELING

NºPublicación: WO2018167283A1 20/09/2018

Solicitante:
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE [FR]
UNIV DAIX MARSEILLE [FR]
INST JEAN PAOLI & IRENE CALMETTES [FR]
CENTRE NAT RECH SCIENT [FR]

Resumen de: WO2018167283A1

The present invention relates to the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDA) associated neural remodeling (PANR). The inventors investigated the effects of the stromal compartment on PDA and PANR and the specific connection between the stromal compartment and the nerve system in PDA. Using PDA samples from human and endogenous mouse models, the inventors demonstrated that LIF (leukemia inhibitory factor) is overexpressed in PDA tissues compared to healthy pancreas while its receptors, LIFR and gp130, are expressed in intra-tumoral nerves. The inventors demonstrated that LIF expression and secretion induced Schwann cell migration, decreased proliferation and modulated their differentiation status. LIF also induced neuronal plasticity. The injection of LIF blocking antibody in endogenous PDA mice model reduces intra-tumoral nerve density. Furthermore, using human and mouse serum libraries, the inventors showed that LIF titer improves CA19.9 diagnostic value and is positively correlated with intra-tumoral nerve density. Thus, the present invention relates to LIF inhibitor for use in the treatment of PANR and a method of identifying a subject having or at risk of having or developing PANR, comprising measuring the expression level of LIF.



traducir


 

METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF MANTLE CELL LYMPHOMAS

NºPublicación: US2018263968A1 20/09/2018

Solicitante:
CELGENE CORP [US]

Resumen de: US2018263968A1

Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.



traducir


 

METHODS FOR DETERMINING RESISTANCE TO ANTICANCER THERAPY AND COMPOSITION USED THEREFOR

NºPublicación: EP3375887A1 19/09/2018

Solicitante:
SD GENOMICS CO LTD [KR]

Resumen de: EP3375887A1

The present invention relates to a pharmaceutical composition for the prevention or treatment of malignant tumors comprising an agent capable of inhibiting the expression of HMGCLL1 IS3, a pharmaceutical composition for the prevention or treatment of malignant tumors showing resistance to tyrosine kinase inhibitors, a method for determining drug resistance in a subject having a malignant tumor using the expression level of HMGCLL1 IS3, a composition and a kit for diagnosing drug resistance used for the method, a method for determining the probability of developing a malignant tumor using the expression level of HMGCLL1 IS3, a method for screening malignant tumor therapeutic agents using the expression level of HMGCLL1 IS3, a method for predicting prognosis of malignant tumors using the expression level of HMGCLL1 IS3, a composition and a kit for predicting the prognosis of malignant tumors including an agent capable of measuring the expression level of HMGCLL1 IS3, a method for determining drug resistance in a subject having a malignant tumor using SNP, a composition and a kit for diagnosing drug resistance used for the method, a method for determining the probability of developing a malignant tumor using SNP, a method for predicting the prognosis of malignant tumors using SNP, and a composition and a kit for predicting the prognosis of malignant tumors used for the method. The method of the present invention can effectively predict or diagnose drug tolerance of a patient wit



traducir


 

ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA

NºPublicación: EP3373919A1 19/09/2018

Solicitante:
CELATOR PHARMACEUTICALS INC [US]
UNIV OREGON HEALTH & SCIENCE [US]

Resumen de: WO2017083592A1

Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.



traducir


 

PRODUCTION OF NUCLEIC ACID

NºPublicación: EP3375870A1 19/09/2018

Solicitante:
THERMO FISHER SCIENTIFIC BALTICS UAB [LT]

Resumen de: EP3375870A1

The present invention provides a method for in vitro evolution of reverse transcriptase enzymes, and enzymes obtainable thereby, in particular those based on Moloney Murine Leukemia Virus reverse transcriptase.



traducir


 

A METHOD FOR PREDICTING THE RESPONSIVENESS OF A PATIENT TO A TREATMENT WITH MTOR INHBITORS

NºPublicación: EP3375888A1 19/09/2018

Solicitante:
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE [FR]
UNIV DE NICE SOPHIA ANTIPOLIS [FR]

Resumen de: EP3375888A1

The present invention relates to a method for predicting the responsiveness of a patient to a treatment with mtor inhbitors. Using primary Eµ-Myc lymphoma cells, inventors observed that Eµ- Myc-GAPDHhigh clones presented less mTOR activity than Eµ-Myc-GAPDHlow clones, as determined by the increase in p70-S6K phosphorylation in the latter. Importantly, inhibition of mTOR with rapamycin in two independent Eµ- Myc-GAPDHlow clones induces a metabolic shift from OxPhos to glycolysis. These results suggest that GAPDH-dependent modulation of the mTOR pathway controls the metabolic status of malignant B lymphocytes. Accordingly, the invention relates to a method for determining whether a subject suffering from lymphoma will achieve a response to a treatment with mTOR inhibitor and to a method of treating with an mTOR inhibitor the subject identified as responder.



traducir


 

AMORPHOUS PANOBINOSTAT AND ITS LACTATE SALT

NºPublicación: WO2018163114A1 13/09/2018

Solicitante:
SHILPA MEDICARE LTD [IN]

Resumen de: WO2018163114A1

The present invention relates to an amorphous form of Panobinostat Lactate hydrate. In particular, the present invention relates to processes for the preparation of amorphous form of Panobinostat Lactate. More particular the present invention relates to the pharmaceutical composition comprising an amorphous Panobinostat Lactate and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of Multiple myeloma. The present invention relates to an amorphous form of Panobinostat and its process for the preparation thereof.



traducir


 

T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA

NºPublicación: US2018258187A1 13/09/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
EUREKA THERAPEUTICS INC [US]

Resumen de: US2018258187A1

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.



traducir


 

PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS LENALIDOMIDE AND AN ANTIOXIDANT

NºPublicación: US2018256501A1 13/09/2018

Solicitante:
SYNTHON BV [NL]

Resumen de: US2018256501A1

The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.



traducir


 

MULTIPLE MYELOMA TREATMENT

NºPublicación: US2018256521A1 13/09/2018

Solicitante:
VANDA PHARMACEUTICALS INC [US]

Resumen de: US2018256521A1

The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).



traducir


 

Method and kit for testing chronic myelogenous leukemia (CML), method for isolating TKI-resistant CML cells, and agent for reducing TKI-resistance of CML and method for screening the same

NºPublicación: US2018259530A1 13/09/2018

Solicitante:
UNIV TOKYO [JP]

Resumen de: US2018259530A1

One or more embodiments of the invention relate to a testing method and kit for testing chronic myelogenous leukemia (CML). One or more embodiments of the invention also relate to a method for isolating tyrosine kinase inhibitor (TKI)-resistant CML cells. One or more embodiments of the invention also relate to an agent for reducing TKI resistance in CML, and to a screening method for the same.



traducir


 

METHODS FOR TREATMENT OR PREVENTION OF LEUKEMIA

NºPublicación: WO2018165482A1 13/09/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: WO2018165482A1

The present disclosure relates generally to methods for preventing, ameliorating or treating leukemia. In particular, the present disclosure relates to administering a therapeutically effective amount of at least one agent to reduce the expression of synaptotagmin-binding, cytoplasmic RNA-interacting protein (SYNCRIP) to a subject diagnosed with, or at risk for acute myeloid leukemia (AML).



traducir


 

MOUSE LYMPHOMA CELL LINE AND ANIMAL MODEL OF HUMAN HIGH GRADE B-CELL LYMPHOMA

NºPublicación: US2018255752A1 13/09/2018

Solicitante:
PECSI TUDOMANYEGYETEM [HU]

Resumen de: US2018255752A1

The invention relates to a new, spontaneous mouse lymphoma cell line displaying CD19, B220, MHC II, surface IgG2a/kappa chain and MAC-1, which is negative for CD5, animal models of B-cell lymphoma based on said cell line and methods for assessing lymphoma propagation and lymphoma expansion based on said cell line.



traducir


 

DIAGNOSTIC METHODS FOR IDENTIFYING T-CELL LYMPHOMA AND LEUKEMIA BY HIGH-THROUGHPUT TCR-BETA SEQUENCING

NºPublicación: US2018258492A1 13/09/2018

Solicitante:
KARKINOS PREC ONCOLOGY LLC [US]

Resumen de: US2018258492A1

A method for diagnosing a lymphoid proliferative disorder (such as lymphoma, T-cell lymphoma or leukemia) in a subject or determining the risk of a subject for a lymphoid proliferative disorder recurrence after transient remission, which includes high throughput T-Cell Receptor β (TCRβ) sequencing tests to identify dominant oncogenic clones in the subject suffering from the lymphoid proliferative disorder. Oligonucleotides primer compositions and kits associated with the above-described methods are also provided herein. Said subject includes living organisms, such as mammals (e.g., dogs, cats, pigs, cows, horses, goats, rabbits, humans), non-mammalian vertebrates, such as birds (e.g., chicken, ducks), fish (e.g., sharks), or frogs, and transgenic species thereof.



traducir


 

SUBSTITUTED INDOLE MCL-1 INHIBITORS

NºPublicación: US2018258039A1 13/09/2018

Solicitante:
UNIV VANDERBILT [US]

Resumen de: US2018258039A1

The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.



traducir


 

ANTI-S100A8 FOR TREATING LEUKEMIA

NºPublicación: US2018256710A1 13/09/2018

Solicitante:
UNIV LAVAL [CA]

Resumen de: US2018256710A1

The present description relates to an anti-S1008 protein for treating leukemia. More specifically, is disclosed anti-S100A8 antibody that specifically binds to a portion of S100A8 protein and/or a S100A8/S100A9 heterodimer for treating leukemia.



traducir


 

SOLID STATE FORMS OF MIDOSTAURIN

NºPublicación: WO2018165071A1 13/09/2018

Solicitante:
TEVA PHARMACEUTICAL WORKS LTD [HU]
TEVA PHARMA [US]

Resumen de: WO2018165071A1

The present disclosure relates to solid state forms of Midostaurin, processes for preparation thereof, pharmaceutical compositions thereof, and use thereof in the treatment of Acute Myelogenous Leukemia (AML) and Aggressive Systemic Mastocytosis. Chemical formula: C35H30N4O4 Molecular mass: 570.64 g/mol



traducir


 

BIOMARKER FOR OUTCOME IN AML PATIENTS

NºPublicación: WO2018162404A1 13/09/2018

Solicitante:
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDICALE [FR]
UNIV DAIX MARSEILLE [FR]
INST JEAN PAOLI & IRENE CALMETTES [FR]
CENTRE NAT RECH SCIENT [FR]

Resumen de: WO2018162404A1

The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML). The inventors have reported that NK cells in AML patients display marked differences in NK maturation compared to healthy subjects, defining three distinct groups of patients according to NK maturation profiles. In this study, they analyzed the maturation profile of NK cells in in a large multicenter cohort (87 patients) allowing them to statistically examine the impact of maturation defects on the clinical outcome of patients. Thus, the invention relates to a method for predicting the survival time of a patient suffering from AML comprising i) determining in a sample obtained from the patient the proportion of NK cells expressing CD56bright, CD56dim, CD57 and KIR ii) dividing the NK cells is 5 different clusters and iii) providing a good or bad prognosis in function of the proportion of the different clusters.



traducir


 

Methods and compositions for transducing lymphocytes and regulated expansion thereof

NºPublicación: AU2017236796A1 13/09/2018

Solicitante:
F1 ONCOLOGY INC

Resumen de: AU2017236796A1

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including ribos witches that are controlled, for example in vivo, by nucleoside analogues.



traducir


 

INHIBITORS OF MALT1 AND USES THEREOF

NºPublicación: WO2018165385A1 13/09/2018

Solicitante:
UNIV CORNELL [US]
CHILDRENS MEDICAL CENTER [US]
DANA FARBER CANCER INST INC [US]

Resumen de: WO2018165385A1

Provided herein are compounds that inhibit MALTl, a protein whose activity is responsible for constitutive NF-κΒ signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALTl -related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.



traducir


 

"MOBILIZING LEUKEMIA CELLS"

NºPublicación: EP3370734A1 12/09/2018

Solicitante:
LOS ANGELES CHILDRENS HOSPITAL [US]
ANTISENSE THERAPEUTICS LTD [AU]

Resumen de: WO2017075670A1

A method for mobilizing leukemia cells which are α4 integrin positive to the peripheral blood of a human subject, the method comprising administering to the human subject an effective amount of an antisense compound to α4 integrin. The cells may be mobilized from bone marrow. The antisense compound is: 5' - MeCMeUG AGT MeCTG TTT MeUMeCMeC AMeUMeU MeCMeU - 3' wherein, (a) each of the 19 internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate diester; (b) the nucleotides at the positions 1 to 3 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; (c) the nucleotides at the positions 4 to 12 from the 5' end are 2'- deoxyribonucleosides; (d) the nucleotides at the positions 13 to 20 from the 5' end are 2'-O-(2-methoxyethyl) modified ribonucleosides; and (e) all cytosines are 5- methylcytosines (MeC), or a pharmaceutically acceptable salt thereof.



traducir


 

PYRIMIDINE DERIVATIVE AND USE THEREOF

Nº publicación: EP3372594A1 12/09/2018

Solicitante:
HUMANWELL HEALTHCARE GROUP CO LTD [CN]

Resumen de: EP3372594A1

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R 1 , R 2 , R 3 , R 4 and R 5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver